Table 1 Characteristics of included studies
Study | Year | Number of patients | Disease stage | NLR cutoff value |
|---|---|---|---|---|
Overall survival | ||||
Azab et al. [23]a | 2012 | 316 | Mixed | 3.3 |
Azab et al. [13]a | 2013 | 437 | Mixed | 3.3 |
Bozkurt et al. [24] | 2015 | 85 | Early | 2.0 |
Dirican et al. [25] | 2015 | 1527 | Mixed | 4.0 |
Forget et al. [10] | 2014 | 720 | Early | 3.3 |
Jia et al. [14] | 2015 | 1570 | Early | 2.0 |
Koh et al. [8] | 2014 | 157 | Early | 2.3 |
Koh et al. [15] | 2015 | 1435 | Mixed | 5.0 |
Nakano et al. [9] | 2015 | 167 | Early | 2.5 |
Noh et al. [26]a | 2013 | 442 | Early | 2.5 |
Pistelli et al. [27] | 2015 | 90 | Early | 3.0 |
Rimando et al. [28] | 2016 | 461 | Mixed | 3.8 |
Yao et al. [11] | 2014 | 608 | Early | 2.6 |
Disease-free survival | ||||
Asano et al. [12] | 2016 | 61 | Early | 3.0 |
Bozkurt et al. [24] | 2015 | 85 | Early | 2.0 |
Dirican et al. [25] | 2015 | 1527 | Mixed | 4.0 |
Forget et al. [10] | 2014 | 720 | Early | 3.3 |
Hong et al. [29] | 2015 | 487 | Early | 1.9 |
Jia et al. [14] | 2015 | 1570 | Early | 2.0 |
Koh et al. [8] | 2014 | 157 | Early | 2.3 |
Nakano et al. [9] | 2015 | 167 | Early | 2.5 |
Pistelli et al. [27] | 2015 | 90 | Early | 3.0 |